Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

Lung Cancer

Volumn 83, Issue 3, 2014, Pages 383-388

  Macerelli, M ^a,b   Caramella, C ^a   Faivre, L ^a   Besse, B ^a   Planchard, D ^a   Polo, V ^a,c   Ngo Camus, M ^a   Celebic, A ^a   Koubi Pick, V ^d   Lacroix, L ^d   Pignon, J P ^a   Soria, J C ^a  

^a Gustave Roussy ^*  (France)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

^c Venetian Oncology Institute   (Italy)

^d Translational Research Laboratory   (France)

Author keywords

Advanced non small cell lung cancer; Chemoresistance; KRAS; Platinum based chemotherapy; Specific point mutations; Tumor aggressiveness

Indexed keywords

ADVANCED NON-SMALL CELL LUNG CANCER; CHEMORESISTANCE; KRAS; PLATINUM-BASED CHEMOTHERAPY; SPECIFIC POINT MUTATIONS; TUMOR AGGRESSIVENESS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84894253032     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.12.013     Document Type: Article

References (37)

1. Jacoulet N.P., Gainet M., Elleuch R. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine. J Thorac Oncol 2009, 4:1544-1549.
2. Sekine H.I., Horinouchi H., Nokihara H., Yamamoto N., Kubota K., Tamura T. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2012, 13:39-43.
3. Langer C.J., Mok T., Postmus P.E. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treat Rev 2013, 39:252-260.
4. Liu P., Morrison C., Wang L., Xiong D., Vedell P., Cui P., et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012, 33:1270-1276.
5. Li T., Kung H.J., Mack P.C., Gandara D.R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013, 31:1039-1049.
6. Hirsch F.R., Jänne P.A., Eberhardt W.E., Cappuzzo F., Thatcher N., Pirker R., et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013, 8:373-384.
7. Reungwetwattana T., Weroha S.J., Molina J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer 2012, 13:252-266.
8. Scrima M., De Marco C., Fabiani F., Franco R., Pirozzi G., Rocco G., et al. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS ONE 2012, 7:e30427.
9. Lin Y.A.R.K., Tsai Y.T., Hsu H.S., Yang Y.C., Chen C.Y., Wang Y.C. MDM2 overexpression deregulates the transcriptional control of RB/E2F leading to DNA methyltransferase 3A overexpression in lung cancer. Clin Cancer Res 2012, 18:4325-4333.
10. Cui G.H., Wu Y.S., Zhang Q.Y., Gao X.J.Y.F. Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer. Med Oncol 2013, 30:437.
11. Chin L.P., Soo R.A., Soong R., Ou S.H.I. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 2012, 7:1625-1630.
12. Oxnard G.R., Binder A., Jänne P. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013, 31:1097-1104.
13. Larsen J.M. Molecular biology of lung cancer: clinical implications. Clin Chest Med 2011, 32:703-740.
14. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J., et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323:561-565.
15. Shankaran V., Obel J., Benson A.B. Predicting response to EGFR inhibitors in metastatic colorectal cancer: current practice and future directions. Oncologist 2010, 15:157-167.
16. Suda K., Tomizawa K., Mitsudomi T. Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev 2010, 29:49-60.
17. Califano R., Landi L. Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer. Drugs 2012, 72(Suppl. 1):28-36.
18. Shepherd F.A., Domerg C., Hainaut P., Janne P.A., Pignon J.P., Graziano S., et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013, 31:2173-2181.
19. Mordant Y.P., Deutsch E., Olaussen K.A., Soria J.C. Are RAS mutations predictive markers of resistance to standard chemotherapy?. Nat Rev Clin Oncol 2009, 6:528-534.
20. Ihle N.T., Byers L., Kim E.S., Saintigny P., Lee J.J., Blumenschein G.R., et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012, 104:228-239.
21. Gomez-Roca C., Koscielny S., Ribrag V., Dromain C., Marzouk I., Bidault F., et al. Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer 2011, 47:2512-2516.
22. Mehrara E., Forssell-Aronsson E., Bernhardt P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br J Cancer 2011, 105:682-686.
23. Rodenhuis S., Van de Wetering M.L., Mooi W.J., Evers S.G., Van Zandwijk N., Bos J.L. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987, 317:929-935.
24. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005, 92:131-139.
25. Rodenhuis S., Slebos R.J., Boot A.J., Evers S.G., Mooi W.J., Wagenaar S.S., et al. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Cancer Res 1988, 48:5738-5741.
26. Riely G.J., Kris M.G., Rosenbaum D., marks J., Li A., Chitale D.A., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734.
27. Martin P., Leighl N.B., Tsao M.S., Shepherd F.A. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013, 8:530-542.
28. Cadranel J., Mauguen A., Faller M., Zalcman G., Buisine M.P., Westeel V., et al. Impact of systematic EGFR and KRAS mutation evaluatio on progression-free survival and overall survival inpatients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project-part 2). J Thorac Oncol 2012, 7:1490-1502.
29. Metro G., Chiari R., Duranti S., Siggillino A., Fischer M.J., Giannarelli D., et al. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype. Lung Cancer 2012, 78:81-86.
30. Janne P.A., Shaw A.T., Pereira J.R., Jeannin G., Vansteenkiste J., Barrios C., et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013, 14:38-47.
31. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
32. Rosell R., Molina F., Moreno I., Martinez E., Pifarré A., Font A., et al. Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 1995, 12(Suppl. 1):S59-S70.
33. Tsao M.S., Aviel-Ronen S., Ding K., lau D., Liu N., Sakura A., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007, 25:5240-5247.
34. Moran D.M., Trusk P., Shell S.A., Camidge D.R., Doebele R.C., Berge E.M., et al. Abstract LB-449: KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small-cell lung cancer. Cancer Res 2012, 72:LB-449. 10.1158/1538-7445.am-lb-449.
35. Kamdar M.K., Parent T., Walker P.R. KRAS gene mutation status and sensitivity to pemetrexed: a retrospective analysis. J Clin Oncol 2013, 31(Suppl.). [abstract e19154].
36. Doebele R.C., Lu X., Sumey C., Maxson D.A., Weickardt A.J., Oton A.B., et al. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer 2012, 118:4502-4511.
37. Hendriks L., Vosse B., Speel E., Bootsman G., Westenend M., de Vries G., et al. EGFR mutated patients (pts): different pattern and outcome of metastatic bone disease (MBD) and brain metastasis (BM)?. Lung Cancer 2013, 80(Suppl. 1):S30-S40.